AKRO Investors Have Opportunity to Lead Akero Therapeutics,
LOS ANGELES, June 18, 2024 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. (“Akero” or “the Company”) (NASDAQ: AKRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the